Login to Your Account

Other News To Note

Friday, October 28, 2011

• Alexza Pharmaceuticals Inc., of Mountain View, Calif., submitted a marketing authorization application to the European Medicines Agency for its Adasuve (loxapine) for the rapid control of agitation in adult patients with schizophrenia or bipolar disorder. Adasuve uses Alexza's Staccato oral inhalation technology. Grupo Ferrer International SA, of Barcelona, Spain, has commercial rights to Adasuve in Europe, Latin America, Russia and the Commonwealth of Independent States.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription